Leucadia Technologies

Leucadia Therapeutics is a preclinical-stage biotechnology company developing a novel approach to treating Alzheimer's disease by addressing the physical causes of toxic metabolite buildup in the brain. The company's core technology, Arethusa, is a specialized medical device designed to restore the drainage of cerebrospinal fluid (CSF) through the cribriform plate, a porous bone structure that often becomes occluded with age. By improving the clearance of amyloid-beta and other metabolic waste products, Leucadia aims to prevent the progression of neurodegeneration. Based in Carlsbad, California, the company is advancing its platform to provide a long-term solution for cognitive decline that differs from traditional systemic drug therapies.